Status:
WITHDRAWN
RCT ALB for SA Cysticercosis
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Subarachnoid Cysticercosis
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
This study will enroll 120 individuals diagnosed with subarachnoid cysticercosis, a disease caused by the invasion of the basal part of your brain by a parasite named Taenia solium. Subarachnoid cysti...
Detailed Description
This is a randomized, double blind comparison of two lengths of albendazole thereapy for subarachnoid cysticercosis. It will enroll 120 individuals, male and female age 18 to 65, and diagnosed with su...
Eligibility Criteria
Inclusion
- Male or female individuals between 18-65 year of age with a diagnosis of basal subarachnoid cysticercosis, based on MRI and confirmed by serological test.
- Willingness to accomplish the two weeks minimal hospitalization required.
- Female of child-bearing potential willing to use an adequate method of contraception including implants, injectables, combined oral contraceptives, effective intrauterine devices, sexual abstinence, or vasectomized partner while participating in the study.
- Patients with normal laboratory values for hemoglobin, platelet counts, total white blood cells, glucose, creatinine, bilirubin, ALT, AST, and electrolytes.
- Negative fecal exam for Taenia eggs.
Exclusion
- Previous therapy with albendazole (does not include patients who received single-dose 400 mg ABZ for intestinal parasites), or praziquantel.
- Pulmonary tuberculosis evidenced by a positive chest X-ray and positive sputum smears.
- Pre-existing diagnosis of diabetes
- Systemic disease other than NCC that may affect therapy or short-term prognosis, including but not limited to chronic renal failure, hepatic insufficiency, cardiac failure, and steroid-dependent immune diseases. Identification of systemic diseases will be left to the discretion of each Site PI.
- Patients in unstable condition or with severe intracranial hypertension (ICH). Definition of severe ICH for this study would be the presence of headaches, nausea, and vomiting and papilledema at fundoscopic examination (all of them). Patients in this category can be considered for entrance into the study only after treatment of ICH by ventricle-peritoneal shunting. Patients with CT findings compatible with intracranial hypertension will have neurosurgical evaluation (by non study personal) before study entry.
- Pregnancy
- History of hypersensitivity to albendazole
- Concurrent treatment with praziquantel, cimetidine or teophylline.
- Chronic alcohol or drug abuse
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00133458
End Date
June 1 2007
Last Update
January 30 2019
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Facultad de Medicina de Riberao
Riberao Preto, Brazil, 14020-380
2
Instituto Neurologico de Antioquia
Medellín, Colombia
3
Neurology Service, Hospital -Clinica Kennedy
Guayaquil, Ecuador
4
Universidad Peruana Cayetano Heredia
Lima, Peru